{"pmid":32332075,"title":"Patients with lupus are not protected from COVID-19.","text":["Patients with lupus are not protected from COVID-19.","Ann Rheum Dis","Sawalha, Amr H","32332075"],"journal":"Ann Rheum Dis","authors":["Sawalha, Amr H"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32332075","week":"202017|Apr 20 - Apr 26","doi":"10.1136/annrheumdis-2020-217656","keywords":["autoimmunity","hydroxychloroquine","lupus erythematosus, systemic"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1665071049663840256,"score":8.518259,"similar":[{"pmid":32332072,"title":"Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.","text":["Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.","Ann Rheum Dis","Mathian, Alexis","Mahevas, Matthieu","Rohmer, Julien","Roumier, Mathilde","Cohen-Aubart, Fleur","Amador-Borrero, Blanca","Barrelet, Audrey","Chauvet, Cecile","Chazal, Thibaud","Delahousse, Michel","Devaux, Mathilde","Euvrard, Romain","Fadlallah, Jehane","Florens, Nans","Haroche, Julien","Hie, Miguel","Juillard, Laurent","Lhote, Raphael","Maillet, Thibault","Richard-Colmant, Gaelle","Palluy, Jean Baptiste","Pha, Micheline","Perard, Laurent","Remy, Philippe","Riviere, Etienne","Sene, Damien","Seve, Pascal","Morelot-Panzini, Capucine","Viallard, Jean-Francois","Virot, Jean-Simon","Benameur, Neila","Zahr, Noel","Yssel, Hans","Godeau, Bertrand","Amoura, Zahir","32332072"],"journal":"Ann Rheum Dis","authors":["Mathian, Alexis","Mahevas, Matthieu","Rohmer, Julien","Roumier, Mathilde","Cohen-Aubart, Fleur","Amador-Borrero, Blanca","Barrelet, Audrey","Chauvet, Cecile","Chazal, Thibaud","Delahousse, Michel","Devaux, Mathilde","Euvrard, Romain","Fadlallah, Jehane","Florens, Nans","Haroche, Julien","Hie, Miguel","Juillard, Laurent","Lhote, Raphael","Maillet, Thibault","Richard-Colmant, Gaelle","Palluy, Jean Baptiste","Pha, Micheline","Perard, Laurent","Remy, Philippe","Riviere, Etienne","Sene, Damien","Seve, Pascal","Morelot-Panzini, Capucine","Viallard, Jean-Francois","Virot, Jean-Simon","Benameur, Neila","Zahr, Noel","Yssel, Hans","Godeau, Bertrand","Amoura, Zahir"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32332072","week":"202017|Apr 20 - Apr 26","doi":"10.1136/annrheumdis-2020-217566","keywords":["hydroxychloroquine","lupus erythematosus, systemic","lupus nephritis"],"source":"PubMed","weight":0,"e_drugs":["Hydroxychloroquine"],"_version_":1665071049651257344,"score":118.19444},{"pmid":32327429,"title":"Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit.","text":["Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit.","Ann Rheum Dis","Monti, Sara","Montecucco, Carlomaurizio","32327429"],"journal":"Ann Rheum Dis","authors":["Monti, Sara","Montecucco, Carlomaurizio"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32327429","week":"202017|Apr 20 - Apr 26","doi":"10.1136/annrheumdis-2020-217524","keywords":["antirheumatic agents","hydroxychloroquine","lupus erythematosus, systemic"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Calado"],"e_drugs":["Hydroxychloroquine"],"_version_":1664996914763923458,"score":107.47773},{"pmid":32327426,"title":"SLE patients are not immune to covid-19: importance of sending the right message across.","text":["SLE patients are not immune to covid-19: importance of sending the right message across.","Ann Rheum Dis","Goyal, Mohit","32327426"],"journal":"Ann Rheum Dis","authors":["Goyal, Mohit"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32327426","week":"202017|Apr 20 - Apr 26","doi":"10.1136/annrheumdis-2020-217658","keywords":["autoimmune diseases","communicable diseases, imported","epidemiology","hydroxychloroquine","lupus erythematosus, systemic"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664996914912821248,"score":99.450714},{"pmid":32317315,"title":"Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?","text":["Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?","Ann Rheum Dis","Moiseev, Sergey","Avdeev, Sergey","Brovko, Michail","Novikov, Pavel","Fomin, Victor","32317315"],"journal":"Ann Rheum Dis","authors":["Moiseev, Sergey","Avdeev, Sergey","Brovko, Michail","Novikov, Pavel","Fomin, Victor"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317315","week":"202017|Apr 20 - Apr 26","doi":"10.1136/annrheumdis-2020-217570","keywords":["autoimmune diseases","hydroxychloroquine","lupus erythematosus, systemic"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Chloroquine","Hydroxychloroquine"],"_version_":1664815087635922945,"score":94.96599},{"pmid":32317220,"title":"The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19.","text":["The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19.","The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has posed the world at a pandemic risk. Coronavirus-19 disease (COVID-19) is an infectious disease caused by SARS-CoV-2, which causes pneumonia, requires intensive care unit hospitalization in about 10% of cases and can lead to a fatal outcome. Several efforts are currently made to find a treatment for COVID-19 patients. So far, several anti-viral and immunosuppressive or immunomodulating drugs have demonstrated some efficacy on COVID-19 both in vitro and in animal models as well as in cases series. In COVID-19 patients a pro-inflammatory status with high levels of interleukin (IL)-1B, IL-1 receptor (R)A and tumor necrosis factor (TNF)-alpha has been demonstrated. Moreover, high levels of IL-6 and TNF-alpha have been observed in patients requiring intensive-care-unit hospitalization. This provided rationale for the use of anti-rheumatic drugs as potential treatments for this severe viral infection. Other agents, such as hydroxychloroquine and chloroquine might have a direct anti-viral effect. The anti-viral aspect of immunosuppressants towards a variety of viruses has been known since long time and it is herein discussed in the view of searching for a potential treatment for SARS-CoV-2 infection.","J Autoimmun","Perricone, Carlo","Triggianese, Paola","Bartoloni, Elena","Cafaro, Giacomo","Bonifacio, Angelo F","Bursi, Roberto","Perricone, Roberto","Gerli, Roberto","32317220"],"abstract":["The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has posed the world at a pandemic risk. Coronavirus-19 disease (COVID-19) is an infectious disease caused by SARS-CoV-2, which causes pneumonia, requires intensive care unit hospitalization in about 10% of cases and can lead to a fatal outcome. Several efforts are currently made to find a treatment for COVID-19 patients. So far, several anti-viral and immunosuppressive or immunomodulating drugs have demonstrated some efficacy on COVID-19 both in vitro and in animal models as well as in cases series. In COVID-19 patients a pro-inflammatory status with high levels of interleukin (IL)-1B, IL-1 receptor (R)A and tumor necrosis factor (TNF)-alpha has been demonstrated. Moreover, high levels of IL-6 and TNF-alpha have been observed in patients requiring intensive-care-unit hospitalization. This provided rationale for the use of anti-rheumatic drugs as potential treatments for this severe viral infection. Other agents, such as hydroxychloroquine and chloroquine might have a direct anti-viral effect. The anti-viral aspect of immunosuppressants towards a variety of viruses has been known since long time and it is herein discussed in the view of searching for a potential treatment for SARS-CoV-2 infection."],"journal":"J Autoimmun","authors":["Perricone, Carlo","Triggianese, Paola","Bartoloni, Elena","Cafaro, Giacomo","Bonifacio, Angelo F","Bursi, Roberto","Perricone, Roberto","Gerli, Roberto"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317220","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jaut.2020.102468","keywords":["autoimmunity","biologics","covid-19","coronavirus","dmards","il-6","immunosuppressant. il-1","infection","rheumatic","sars-cov-2","tdmards"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Chloroquine","Hydroxychloroquine"],"_version_":1664815087679963136,"score":72.929245}]}